Updated data from post-hoc analyses from a Phase 3 clinical trial, PACIFIC, evaluating AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab) in patients with unresectable Stage 3 non-small lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT) showed a significant survival benefit. The results were presented virtually at ESMO.
The estimated four-year overall survival (OS) rate was 49.6% in the Imfinzi group, compared to 36.3% in the control group after CRT. Median OS was much greater in Imfinzi-treated patients, 47.5 months versus 29.1 months. With a maximum treatment course of one year, ~35.3% patients receiving Imfinzi had not progressed after four years, compared to 19.5% for placebo.
The results build on data published in the New England Journal of Medicine in 2018.
Exploratory subgroup analyses from another Phase 3, CASPIAN, evaluating Imfinzi + chemo in patients with extensive-stage small cell lung cancer (SCLC), showed that more than 3x (17% vs. 4.5%) were alive and progression-free for a year or more compared to chemo alone.
https://seekingalpha.com/news/3615237-astrazenecas-imfinzi-extends-survival-in-lung-cancer-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.